Resistance to EGFR-TKI therapy is inevitable and osimertinib is an approved NSCLC therapy for patients bearing the EGFR exon 19 deletions or exon 21 L858R mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.